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Cancers progress through clonal evolution, the sequential acquisition of oncogenic mutations through Darwinian selection of advantaged subclones. For example, in colon cancers, adenomatous polyposis coli (*APC*) mutant clones acquire malignancy after further mutation of *K‐Ras*,*p53*, and other genes.[1](#cas12816-bib-0001){ref-type="ref"} While genetic sequencing corroborated cancer\'s clonal evolution, it also revealed remarkable clonal heterogeneity.[2](#cas12816-bib-0002){ref-type="ref"}, [3](#cas12816-bib-0003){ref-type="ref"} A recent study found rampant intratumor genetic divergence, with \~60% of mutations not universally distributed among subclones.[3](#cas12816-bib-0003){ref-type="ref"} Furthermore, in human glioblastoma, coexisting subclones amplified distinct oncogenic receptor tyrosine kinases (epidermal growth factor receptor \[*EGFR*\], *PDGFR*, and *c‐Met*).[4](#cas12816-bib-0004){ref-type="ref"} Clonal heterogeneity could therefore promote subclone cooperation alongside clonal competition. Indeed, interclonal cooperation between subclones potentiated tumorigenesis in mouse‐modeled breast cancer.[5](#cas12816-bib-0005){ref-type="ref"} Excitingly, clonal population dynamics of cancer‐derived, heterogeneous subclones were reproducible across independent xenografts,[6](#cas12816-bib-0006){ref-type="ref"} suggesting that tumor heterogeneity is a tractable problem. While interclonal communication is considered crucial to cancer\'s etiology, detailed *in vivo* mechanisms are lacking.

*Drosophila* genetics enables manipulation of oncogenic cell clones *in vivo*.[7](#cas12816-bib-0007){ref-type="ref"} Remarkably, *Drosophila* tumorigenesis recapitulates aspects of human cancer, including polarity loss, basement‐membrane degradation, and invasion.[8](#cas12816-bib-0008){ref-type="ref"} Accordingly, genetic screens in *Drosophila* have identified evolutionarily conserved tumor‐suppressor genes, including Hippo pathway components.[9](#cas12816-bib-0009){ref-type="ref"}, [10](#cas12816-bib-0010){ref-type="ref"}, [11](#cas12816-bib-0011){ref-type="ref"} Genetic mosaic analysis also revealed an unusual tumor‐promoting cell population that can be called "oncogenic niche cells" (ONCs). Oncogenic niche cells drive non‐autonomous tumor progression through cellular competition and cooperation with surrounding cells (Fig. [1](#cas12816-fig-0001){ref-type="fig"}a). This review describes mechanisms by which ONCs regulate *Drosophila* tumorigenesis and discusses putative ONCs in mammalian cancers.

![Oncogenic niche cells (ONCs) activated by oncoprotein Src. (a) General ONC scheme showing genetically altered clones (green) become ONCs, stimulating surrounding cell overgrowth. (b) Src64B‐overexpressing cells (GFP+) are scarce yet wild‐type tissue overgrows, causing tissue folding. (c) Src64B‐overexpressing cells inactivate Hippo signaling through F‐actin accumulation. Src activation simultaneously triggers JNK, inducing intraclonal death but propagating Yorkie (Yki) to neighboring cells, causing overproliferation.](CAS-106-00000000001651-g001){#cas12816-fig-0001}

Non‐autonomous tumor progression by ONCs {#cas12816-sec-0002}
========================================

Epithelial cells harboring oncogenic mutations can promote their own growth through interactions with surrounding stroma.[12](#cas12816-bib-0012){ref-type="ref"} However, oncogenic mutations can also promote non‐autonomous proliferation as ONCs. ONCs can be induced by cell competition, a process in which normally viable "loser" cells are eliminated by neighboring "winner" cells. Cell competition is triggered by lower translation rates, disrupted apico‐basal polarity, or aberrant signal transduction, and thus functions as a tumor suppressor and developmental regulator.[13](#cas12816-bib-0013){ref-type="ref"}, [14](#cas12816-bib-0014){ref-type="ref"}, [15](#cas12816-bib-0015){ref-type="ref"}, [16](#cas12816-bib-0016){ref-type="ref"} Alongside cell competition, ONCs commonly feature cooperation between the JNK and Hippo pathways. Below, we describe five classes of ONCs characterized in *Drosophila* imaginal epithelia.

Oncoprotein Src {#cas12816-sec-0003}
---------------

Elevation of oncoprotein Src often correlates with tumor malignancy, yet Src\'s role in tumorigenesis remains unclear.[17](#cas12816-bib-0017){ref-type="ref"} Clones of cells overexpressing Src64B (Src; c‐Src homolog) in the *Drosophila* imaginal disc are eliminated by JNK‐dependent cell competition.[18](#cas12816-bib-0018){ref-type="ref"}, [19](#cas12816-bib-0019){ref-type="ref"} However, Src clones also function as ONCs to cause non‐autonomous overgrowth of surrounding tissue (Fig. [1](#cas12816-fig-0001){ref-type="fig"}b).[19](#cas12816-bib-0019){ref-type="ref"} Src‐activated cells accumulate intracellular F‐actin and activate the Hippo pathway effector Yorkie (Yki; YAP homolog). Simultaneously, JNK signaling induces cell death in a cell‐autonomous manner but propagates Yki to neighboring cells, causing overgrowth of surrounding tissue (Fig. [1](#cas12816-fig-0001){ref-type="fig"}c). Blocking Yki inside Src‐activated cells abolished neighboring Yki activation, implying propagation of Yki from ONCs. Thus, while JNK‐mediated cell competition restrains Src‐activated ONC autonomous growth, JNK--Yki cooperation contributes to non‐autonomous tumorigenesis.

Endocytic dysregulation {#cas12816-sec-0004}
-----------------------

Endocytic trafficking controls internalization and sorting of extracellular molecules and transmembrane proteins. Consequently, endocytic dysregulation disrupts signaling pathways and cell polarity, contributing to human cancers.[20](#cas12816-bib-0020){ref-type="ref"}, [21](#cas12816-bib-0021){ref-type="ref"}, [22](#cas12816-bib-0022){ref-type="ref"} Multiple genetic screens in *Drosophila* identified endosomal sorting complex components *vps25* and *erupted* (*ept*;*tsg101* homolog) as causing non‐autonomous overgrowth.[23](#cas12816-bib-0023){ref-type="ref"}, [24](#cas12816-bib-0024){ref-type="ref"}, [25](#cas12816-bib-0025){ref-type="ref"}, [26](#cas12816-bib-0026){ref-type="ref"} Endocytic ONCs accumulated endosomal Notch, inducing the cytokine Unpaired (Upd; interleukin \[IL\]‐6 homolog) and triggering JAK-- signal transducer and activator of transcription (STAT) signaling in surrounding cells (Fig. [2](#cas12816-fig-0002){ref-type="fig"}a). A similar but distinct endocytic ONC was formed by mutating *Rab5*, an early endosome component. Rab5‐deficient ONCs accumulated EGFR and Eiger (tumor necrosis factor homolog), activating Ras and JNK pathways, respectively.[27](#cas12816-bib-0027){ref-type="ref"} JNK and Ras signaling cooperatively activated Yki, inducing Upd expression and subsequent non‐autonomous overgrowth (Fig. [2](#cas12816-fig-0002){ref-type="fig"}b). Non‐autonomous phenotypes are dependent on cell competition: *vps25* clones prevented from dying autonomously overgrow,[24](#cas12816-bib-0024){ref-type="ref"}, [25](#cas12816-bib-0025){ref-type="ref"} and growth of Rab5 dominant‐negative (*Rab5* ^*DN*^)‐expressing cells was constrained by JNK‐mediated cell competition.[27](#cas12816-bib-0027){ref-type="ref"}, [28](#cas12816-bib-0028){ref-type="ref"} Interestingly, sufficiently large *Rab5* ^*DN*^‐expressing cell clones autonomously overgrow,[28](#cas12816-bib-0028){ref-type="ref"} suggesting that establishment of endocytic ONCs is contingent on cell competition and clone size.

![Endocytic dysregulated oncogenic niche cells (ONCs). (a) *vps25* or *ept* mutant clones accumulate Notch, stimulating secretion of the cytokine Unpaired (Upd) and non‐autonomous overgrowth. (b) *Rab5* mutant cells activate epidermal growth factor receptor (EGFR)--Ras and Eiger--JNK signaling, cooperatively activating Yorkie (Yki) and inducing Upd. STAT, signal transducer and activator of transcription; TNF, tumor necrosis factor.](CAS-106-00000000001651-g002){#cas12816-fig-0002}

Apoptotic stimulus {#cas12816-sec-0005}
------------------

Apoptosis is a hallmark of many cancers and often correlates with increased proliferation and worse prognosis.[29](#cas12816-bib-0029){ref-type="ref"} In *Drosophila* wing discs, massive cell death triggers non‐autonomous "compensatory proliferation", yielding normal adult wings.[30](#cas12816-bib-0030){ref-type="ref"} Yki is activated in dying and neighboring cells and is essential for wing disc regeneration.[31](#cas12816-bib-0031){ref-type="ref"}, [32](#cas12816-bib-0032){ref-type="ref"} Notably, in this case, JNK activation is necessary and sufficient for Yki induction in wing discs,[31](#cas12816-bib-0031){ref-type="ref"} and JNK activity non‐autonomously propagates following local wounding.[33](#cas12816-bib-0033){ref-type="ref"} JNK also stimulates cell migration to the wound site,[34](#cas12816-bib-0034){ref-type="ref"} similar to JNK‐driven developmental or tumorigenic invasion (Fig. [3](#cas12816-fig-0003){ref-type="fig"}a).[35](#cas12816-bib-0035){ref-type="ref"}, [36](#cas12816-bib-0036){ref-type="ref"}

![Apoptotic oncogenic niche cells (ONCs). (a) Damage‐induced JNK activates Yorkie (Yki) in wild‐type cells, triggering compensatory proliferation. Wild‐type cell JNK stimulates migration to the damaged area. (b) "Undead" ONCs formed by overexpression of pro‐apoptotic genes (*Reaper*,*Hid*) and caspase inhibition. Resultant JNK activity stimulates surrounding cell proliferation through ONC Decapentaplegic (Dpp)/Wingless (Wg) secretion. Dcp1, death caspase 1; DIAP1, death‐associated inhibitor of apoptosis 1; drICE,*Drosophila* ICE; Dronc, *Drosophila* NEDD2‐like caspase.](CAS-106-00000000001651-g003){#cas12816-fig-0003}

In a similar phenomenon, when cell death is induced but not executed, typically through overexpression of caspase inhibitor p35, persistent "undead" cells become ONCs and trigger non‐autonomous overgrowth through the growth factors Decapentaplegic (Dpp; bone morphogenetic protein/transforming growth factor‐β homolog) and Wingless (Wg; Wnt homolog).[37](#cas12816-bib-0037){ref-type="ref"}, [38](#cas12816-bib-0038){ref-type="ref"}, [39](#cas12816-bib-0039){ref-type="ref"} In wing discs, this is dependent on a p53‐JNK positive feedback loop activated by the initiator caspase Dronc (Fig. [3](#cas12816-fig-0003){ref-type="fig"}b).[40](#cas12816-bib-0040){ref-type="ref"} Undead cells generated through genomic instability also function as ONCs, secreting Wg and triggering JNK‐dependent non‐autonomous hyperplasia.[41](#cas12816-bib-0041){ref-type="ref"} Here, JNK‐activated MMP1 activity also induces basement membrane degradation and invasion. Intriguingly, undead cells can also cause non‐autonomous apoptosis propagated by Eiger--JNK.[42](#cas12816-bib-0042){ref-type="ref"} Dying ONCs may unleash an autocatalytic wave of JNK, death, growth factor secretion, and proliferation.

Polarity loss {#cas12816-sec-0006}
-------------

Apico‐basal polarity is essential for epithelial cell function and homeostasis. Polarity loss underlies many cancers and is often critical for cancer progression.[43](#cas12816-bib-0043){ref-type="ref"} Imaginal epithelia entirely mutant for conserved apico‐basal polarity genes scribble (*scrib*) or discs large (*dlg*) develop into tumors. However, clones of these mutant cells surrounded by wild‐type cells are eliminated through Eiger--JNK signaling in "tumor‐suppressive cell competition".[44](#cas12816-bib-0044){ref-type="ref"} Competition‐induced JNK also suppresses Yki activity in *scrib* clones.[45](#cas12816-bib-0045){ref-type="ref"} Although JNK restrains overgrowth of *scrib* tissue, it is required for tumor progression and metastasis of *scrib+Ras* ^*V12*^ clones.[35](#cas12816-bib-0035){ref-type="ref"} Surprisingly, distinct *scrib* and *Ras* ^*V12*^ mosaic clones induced in the same imaginal disc still trigger metastasis of *Ras* ^*V12*^ cells,[33](#cas12816-bib-0033){ref-type="ref"} suggesting that *scrib* cells function as ONCs (Fig. [4](#cas12816-fig-0004){ref-type="fig"}a). JNK activity propagates from *scrib* to *Ras* ^*V12*^ cells, inducing Upd and JAK--STAT signaling that cooperates with Ras signaling to induce metastasis. Remarkably, JAK--STAT signaling is also required within *scrib*‐neighboring cells to eliminate *scrib* clones.[33](#cas12816-bib-0033){ref-type="ref"}, [46](#cas12816-bib-0046){ref-type="ref"} As JAK--STAT and JNK both suppress and promote *scrib* tumor formation, competition‐triggered interclonal cooperation likely underlies polarity‐defective ONCs.

![Cooperation between Ras^V12^ and oncogenic niche cells (ONCs). (a) *scrib* cells activate Eiger/JNK signaling, causing neighboring Ras^V12^ cells (purple) to secrete Unpaired (Upd) and metastasize. Alternatively, Ras^V12^/*mito* ^*−/−*^ cells (mitochondrial dysfunction, senescent ONC) generate reactive oxygen species (ROS) and activate p53, which cooperatively activate JNK. JNK and Ras^V12^ inactivate the Hippo pathway, activating Yorkie (Yki) and triggering secretion of Upd and Wingless (Wg). ONC‐induced senescence‐associated secretory phenotype stimulates neighboring Ras^V12^ cell invasion. (b) While Ras^V12^ clones (GFP+) fail to metastasize from the larval brain hemisphere (BH) to the ventral nerve cord (VNC), senescent ONCs (Ras^V12^/*mito* ^*−/−*^) stimulate Ras^V12^ invasion (arrowheads). STAT, signal transducer and activator of transcription; TNF, tumor necrosis factor.](CAS-106-00000000001651-g004){#cas12816-fig-0004}

Ras, mitochondrial dysfunction, and senescence {#cas12816-sec-0007}
----------------------------------------------

Metastasis of Ras^V12^‐expressing cells can be triggered by different ONCs, such as *scrib* clones.[8](#cas12816-bib-0008){ref-type="ref"}, [47](#cas12816-bib-0047){ref-type="ref"} A genetic screen for Ras^V12^‐induced non‐autonomous growth identified mutations in genes required for mitochondrial respiratory function, which are frequently downregulated in various cancers.[48](#cas12816-bib-0048){ref-type="ref"} Clones harboring Ras^V12^ and mitochondrial dysfunction (Ras^V12^/*mito* ^*−/−*^) produce reactive oxygen species (ROS), activating JNK. JNK and Ras cooperatively activate Yki, which upregulates Upd and Wg to induce surrounding tissue overgrowth.[49](#cas12816-bib-0049){ref-type="ref"} Thus, Ras^V12^/*mito* ^*−/−*^ cells act as ONCs. Interestingly, Ras^V12^/*mito* ^*−/−*^ cells cause cell‐cycle arrest through ROS production and undergo p53‐dependent cellular senescence (Fig. [4](#cas12816-fig-0004){ref-type="fig"}a).[50](#cas12816-bib-0050){ref-type="ref"} Overexpression of p53 inside Ras^V12^ clones is sufficient to induce ONCs and non‐autonomous overgrowth. Therefore, senescent cells may function as ONCs through inflammatory cytokine release,[51](#cas12816-bib-0051){ref-type="ref"} a conserved phenomenon called the senescence‐associated secretory phenotype (SASP).[52](#cas12816-bib-0052){ref-type="ref"} Indeed, paralleling *scrib* interclonal cooperation, Ras^V12^/*mito* ^*−/−*^‐produced Upd triggers adjacent Ras^V12^ metastasis (Fig. [4](#cas12816-fig-0004){ref-type="fig"}b).[49](#cas12816-bib-0049){ref-type="ref"} Interestingly, activated Ras signaling stimulates Eiger exocytosis, causing JNK accumulation and JAK--STAT activation at clonal boundaries between Ras^V12^ and wild‐type cells.[53](#cas12816-bib-0053){ref-type="ref"} JNK transcytosis could underlie JNK propagation and cell competition\'s role in oncogenic cooperation.

Oncogenic niche cell themes: JNK‐mediated cell competition and cooperation {#cas12816-sec-0008}
==========================================================================

There are several shared ONC themes (Table [1](#cas12816-tbl-0001){ref-type="table-wrap"}). Notably, Src‐activated, endocytic, and polarity‐defective ONCs undergo JNK‐mediated cell competition. Thus, tumor‐suppressive cell competition is subverted to promote cancer. Cancers may hijack cell competition machinery to "sweep" through populations in field cancerization,[13](#cas12816-bib-0013){ref-type="ref"}, [54](#cas12816-bib-0054){ref-type="ref"} and cell competition also generates ONCs. Ironically, neighboring cells that activate tumor‐suppressive machinery become the cancerous entity they sought to destroy (Fig. [5](#cas12816-fig-0005){ref-type="fig"}). Additionally, JNK is activated following apoptosis, causing non‐autonomous death and proliferation. Thus, a feed‐forward loop of JNK and death could propagate to potentiate tumor progression and metastasis.

###### 

Common oncogenic niche cell (ONC) themes

  -------------------------------------------------------------------------------------------------------------------------------------------
  ONCs                      Competition and cell death   Cooperation        Growth factors   Cellular senescence or p53 accumulation (p53+)
  ------------------------- ---------------------------- ------------------ ---------------- ------------------------------------------------
  Src‐activated             JNK→cell death               JNK→Yki            --               --

  Endocytic dysregulation   JNK→cell death               Notch→JAK--STAT\   Upd\             p53+
                                                         JNK/Ras→Yki        Wg\              
                                                                            Dpp              

  Apoptotic stimulus        Cell death                   JNK→Dpp, Wg\       Wg\              p53+
                                                         JNK→Yki\           Dpp              
                                                         JNK↔p53\                            
                                                         JNK→JNK/death                       

  Polarity defect           JNK→cell death               JNK→JAK--STAT      Upd              --

  Ras^V12^/*mito* ^*−/−*^   --                           JNK/Ras→Yki\       Upd\             p53+, cellular senescence
                                                         ROS/p53→JNK        Wg               
  -------------------------------------------------------------------------------------------------------------------------------------------

Dpp, Decapentaplegic; ROS, reactive oxygen species; STAT, signal transducer and activator of transcription; Upd, UNPAIRED; Wg, Wingless; Yki, Yorkie.

John Wiley & Sons, Ltd

![Oncogenic niche cell (ONC) timeline. Potentially tumorigenic cells (green) are attacked by neighbors through JNK‐based cell competition, causing autonomous cell death. However, dying cells stimulate cooperation between JNK and other pathways, triggering growth factor release and/or non‐autonomous Yorkie (Yki) activation. Senescence also induces ONCs, causing growth factor secretion and potentiating metastasis of adjacent premalignant tissue (i.e. Ras^V12^). Additionally, ONCs may stimulate neighboring cancer stem cell (CSC) proliferation or even induce CSCs, driving non‐autonomous tumor progression. Chemotherapy‐induced death or senescence may contribute to cancer recurrence through formation of ONCs.](CAS-106-00000000001651-g005){#cas12816-fig-0005}

How does JNK drive ONC‐mediated overgrowth? Another ONC theme is JNK‐dependent Yki activation (Table [1](#cas12816-tbl-0001){ref-type="table-wrap"}), which can induce growth factors and anti‐apoptotic genes like *Diap1*. Notably, JNK directly impinges on Hippo through Ajuba‐mediated Warts regulation, activating Yki and driving overgrowth.[55](#cas12816-bib-0055){ref-type="ref"}, [56](#cas12816-bib-0056){ref-type="ref"} Therefore, non‐autonomous JNK propagation in certain ONCs could directly induce non‐autonomous Yki. However, within Src‐activated ONCs, non‐autonomous JNK does not induce Yki. Instead, autonomous JNK cooperatively propagates Yki activity to neighboring cells (Fig. [1](#cas12816-fig-0001){ref-type="fig"}c).[19](#cas12816-bib-0019){ref-type="ref"} Additionally, polarity loss can still induce non‐autonomous Yki activation in tissues lacking the JNK ligand Eiger,[45](#cas12816-bib-0045){ref-type="ref"} suggesting that JNK‐independent pathways may activate non‐autonomous Yki in polarity ONCs. Thus, specific mechanisms of non‐autonomous Yki activation remain unclear. Surprisingly, core Hippo pathway components are not commonly disrupted in human cancer.[57](#cas12816-bib-0057){ref-type="ref"} Instead, Hippo dysregulation may potentiate tumorigenesis through interclonal cooperation. Indeed, Yki/YAP is nuclear in \~60% of hepatocellular carcinomas and 65% of non‐small‐cell lung cancers.[57](#cas12816-bib-0057){ref-type="ref"} Oncogenic niche cell‐driven, non‐autonomous Yki activation could contribute to mammalian cancer progression.

JNK may additionally act through Polycomb group proteins (PcG), which enforce epigenetic repression. During wound‐healing, JNK inactivates PcG to allow fate reprogramming.[58](#cas12816-bib-0058){ref-type="ref"} Therefore, JNK activity could alleviate PcG repression of growth factors like Wg or Upd. Notably, loss of PcG protein Polyhomeotic causes non‐autonomous, Upd‐mediated overgrowth.[59](#cas12816-bib-0059){ref-type="ref"}, [60](#cas12816-bib-0060){ref-type="ref"} Because mammalian JNK can act as a pro‐apoptotic gene linked to tumor regulation,[61](#cas12816-bib-0061){ref-type="ref"} JNK may function in both mammalian and *Drosophila* ONCs.

Oncogenic niche cell hypothesis: Crumbs in ONC establishment {#cas12816-sec-0009}
============================================================

A common ONC theme is cooperative Yki activation (Table [1](#cas12816-tbl-0001){ref-type="table-wrap"}), suggesting that Hippo pathway activity may influence ONCs. Indeed, differential Hippo pathway activity triggers cell competition: Yki‐activated cells are super‐competitors while *yki* mutants are eliminated.[13](#cas12816-bib-0013){ref-type="ref"}, [14](#cas12816-bib-0014){ref-type="ref"}, [16](#cas12816-bib-0016){ref-type="ref"}, [62](#cas12816-bib-0062){ref-type="ref"} Alongside JNK‐based competition, could Hippo‐mediated competition establish ONCs? The apical transmembrane protein Crumbs (Crb) is a good candidate for ONC establishment. Crb recruits Expanded (Ex),[63](#cas12816-bib-0063){ref-type="ref"}, [64](#cas12816-bib-0064){ref-type="ref"}, [65](#cas12816-bib-0065){ref-type="ref"}, [66](#cas12816-bib-0066){ref-type="ref"} activating Hippo and inhibiting Yki. Intriguingly, Crb accumulates in polarity and endocytic ONCs.[26](#cas12816-bib-0026){ref-type="ref"}, [67](#cas12816-bib-0067){ref-type="ref"} Furthermore, Crb‐overexpressing clones are eliminated while *crb* mutants induce neighbor‐cell death in a competitive phenomenon dependent on Crb--Crb extracellular interactions.[68](#cas12816-bib-0068){ref-type="ref"} Therefore, in certain ONCs, high Crb may cause JNK‐dependent repression of Yki and "loser" status. Conversely, neighboring cells with lower Crb would overgrow through JNK‐activated Yki. CRB3 is downregulated in human tumor‐derived cell lines,[43](#cas12816-bib-0043){ref-type="ref"} consistent with lower Crb permitting overgrowth.

However, while Crb‐overexpressing cells are eliminated, overexpression of only Crb\'s intracellular domain (Crb‐intra) causes autonomous overgrowth.[68](#cas12816-bib-0068){ref-type="ref"} Intriguingly, Crb‐intra overgrowth is rescued by depletion of Eiger\'s receptor *Grindelwald*, which colocalizes with Crb at apical membranes.[69](#cas12816-bib-0069){ref-type="ref"} This supports the idea that Crb--JNK might contribute to ONCs, but highlights the complexity of Crb overexpression phenotypes. Indeed, although Crb recruits Ex and activates Hippo, Crb can also promote Ex degradation through ubiquitylation.[66](#cas12816-bib-0066){ref-type="ref"} Moreover, Hippo pathway mutants accumulate Crb yet become super‐competitors,[62](#cas12816-bib-0062){ref-type="ref"}, [70](#cas12816-bib-0070){ref-type="ref"}, [71](#cas12816-bib-0071){ref-type="ref"} perhaps through elevation of anti‐apoptotic DIAP1 or mechanisms paralleling Crb‐intra induced overgrowth. While Crb\'s contribution to ONCs is highly complex, it is likely that Crb and JNK can cooperatively dictate Yki activity and competitive outcomes in ONCs.

Oncogenic niche cell themes: a role for cellular senescence? {#cas12816-sec-0010}
============================================================

Though cell death is common to ONCs, it is not induced in Ras^V12^/*mito* ^*−/−*^ cells, which instead activate p53 and undergo cellular senescence.[50](#cas12816-bib-0050){ref-type="ref"} JNK‐activated Yki stimulates Upd/Wg secretion in a SASP,[50](#cas12816-bib-0050){ref-type="ref"}, [52](#cas12816-bib-0052){ref-type="ref"} reminiscent of growth factor secretion by "undead" ONCs. Intriguingly, p53 has been linked to cell competition. In murine hematopoietic stem cells (HSCs), irradiated p53^−/−^ HSCs outcompete p53^+/+^, but not p53^+/−^ HSCs.[72](#cas12816-bib-0072){ref-type="ref"} Separately, p53 knockdown in differentiated murine tissue allowed disproportionate expansion of p53^−/−^ cells. Surprisingly, p53 knockdown in undifferentiated embryonic stem cells lead to p53^−/−^ cell elimination, suggesting that p53 knockdown triggers context‐dependent cell competition.[73](#cas12816-bib-0073){ref-type="ref"} Supporting this, apoptosis of Myc‐overexpressing, p53^−/−^ *Drosophila* cells was dependent on surrounding neighbors.[74](#cas12816-bib-0074){ref-type="ref"} Furthermore, p53 is intimately linked to JNK in *Drosophila*: p53 and JNK form a feed‐forward loop in undead ONCs,[40](#cas12816-bib-0040){ref-type="ref"} are sufficient to induce each other\'s expression,[40](#cas12816-bib-0040){ref-type="ref"} and p53 directly binds JNK.[75](#cas12816-bib-0075){ref-type="ref"} Indeed, blocking p53 in Ras^V12^/*mito* ^*−/−*^ abrogated JNK activity and ONC formation.[50](#cas12816-bib-0050){ref-type="ref"}

Therefore, p53 or cellular senescence may trigger cell competition and establish ONCs. p53 is elevated in *tsg101* null mice, likely from impaired ubiquitin‐mediated degradation.[76](#cas12816-bib-0076){ref-type="ref"} Ubiquitinated proteins accumulate in *vps25* and *ept* mutant ONCs,[23](#cas12816-bib-0023){ref-type="ref"}, [24](#cas12816-bib-0024){ref-type="ref"}, [26](#cas12816-bib-0026){ref-type="ref"} and mutations in an E1 ubiquitin‐activating enzyme cause non‐autonomous overgrowth.[77](#cas12816-bib-0077){ref-type="ref"} Moreover, p53 is required for undead ONCs' non‐autonomous proliferation.[78](#cas12816-bib-0078){ref-type="ref"} While these phenotypes can partly be explained by p53\'s pro‐apoptotic role, p53 may fuel non‐autonomous tumor progression through cell competition and SASP. As p53 is frequently mutated in human cancers,[79](#cas12816-bib-0079){ref-type="ref"} dysregulated cell competition or SASP may contribute to mammalian cancer progression (see below).

Oncogenic niche cells in mammalian cancer {#cas12816-sec-0011}
=========================================

Do ONCs contribute to mammalian cancer progression? Although cellular senescence can suppress tumor formation, it can fuel non‐autonomous overgrowth through cytokine secretion in a SASP.[52](#cas12816-bib-0052){ref-type="ref"} Mammalian studies also suggest that SASP can drive non‐autonomous tumor progression.[52](#cas12816-bib-0052){ref-type="ref"} Senescence‐associated secretory phenotype of murine hepatic stellate cells potentiated hepatocellular carcinoma formation.[80](#cas12816-bib-0080){ref-type="ref"} Moreover, SASP in epithelial cells triggered malignancy through paracrine secretion of IL‐6 and IL‐8,[81](#cas12816-bib-0081){ref-type="ref"} paralleling senescent ONCs' induction of neighboring Ras^V12^ metastasis (Fig. [4](#cas12816-fig-0004){ref-type="fig"}b). Thus, non‐autonomous tumor progression through cellular senescence and SASP seems conserved in mammalian cancer progression. Like cell competition, cellular senescence can suppress or promote tumorigenesis. As chemotherapy often potentiates cellular senescence,[52](#cas12816-bib-0052){ref-type="ref"}, [82](#cas12816-bib-0082){ref-type="ref"} senescent ONCs could contribute to cancer recurrence (Fig. [5](#cas12816-fig-0005){ref-type="fig"}).

Alongside cellular senescence, cell death is commonly observed in human cancers and often correlates with increased tissue proliferation.[29](#cas12816-bib-0029){ref-type="ref"} In a mouse model of hepatocellular carcinogenesis, dying hepatocytes activate JNK and ROS, inducing proliferation of surrounding cells through cytokine release.[83](#cas12816-bib-0083){ref-type="ref"}, [84](#cas12816-bib-0084){ref-type="ref"} Importantly, therapy‐induced death can also trigger ONC‐mediated proliferation. Following radiotherapy, dying cancer cells activate effector caspases 3/7, triggering prostaglandin E~2~ (PGE~2~) secretion. Subsequently, PGE~2~ stimulates neighbor‐cell proliferation.[85](#cas12816-bib-0085){ref-type="ref"} Notably, tumor recurrence positively correlated with high activation of caspases 3/7 in human patients.[85](#cas12816-bib-0085){ref-type="ref"} In human prostate cancer, chemotherapy‐induced PGE~2~ can trigger non‐autonomous cell proliferation and tumor repopulation through cancer stem cells (see below).[86](#cas12816-bib-0086){ref-type="ref"} Thus, cell death and cellular senescence in ONCs can initiate tumors and hinder treatment (Fig. [5](#cas12816-fig-0005){ref-type="fig"}).

Oncogenic niche cells may promote tumorigenesis through non‐autonomous effects on cancer stem cells (CSCs). The CSC hypothesis proposes that specialized stem cells contribute disproportionately to cancerous populations.[87](#cas12816-bib-0087){ref-type="ref"} Consequently, cancer heterogeneity can be partially attributed to differentiation hierarchies stemming from distinct CSC subpopulations.[2](#cas12816-bib-0002){ref-type="ref"} Experimental evidence suggests that CSC progeny are surprisingly plastic in their fate and can dedifferentiate to CSCs.[87](#cas12816-bib-0087){ref-type="ref"} Intriguingly, a pulse of Src activity was sufficient to convert a non‐malignant breast cell line into a self‐renewing, CSC‐containing cancer through an IL‐6/nuclear factor‐κB positive feedback loop.[88](#cas12816-bib-0088){ref-type="ref"} Furthermore, IL‐6 addition to regular cancer cells induced dedifferentiation to CSCs.[89](#cas12816-bib-0089){ref-type="ref"} As ONCs frequently induce Upd/IL‐6 (Table [1](#cas12816-tbl-0001){ref-type="table-wrap"}) through JNK--Yki cooperation in *Drosophila*, ONC‐secreted factors could promote non‐autonomous CSC induction. Concomitantly, ONCs could promote CSC proliferation, such as in therapy‐induced CSC proliferation and repopulation.[87](#cas12816-bib-0087){ref-type="ref"} Notably, in human hepatocellular carcinoma, JNK and IL‐6 markers are commonly associated with CSCs,[61](#cas12816-bib-0061){ref-type="ref"} although no evidence directly links CSCs to ONCs. Additionally, as CSCs are often resistant to apoptosis,[87](#cas12816-bib-0087){ref-type="ref"} it is possible that CSCs themselves could function as "undead" ONCs when challenged with apoptotic stimuli, such as chemotherapy.

Conclusions {#cas12816-sec-0012}
===========

*Drosophila* studies have brought insight to tumor progression through genetic dissection of ONCs. As senescent and dying ONCs are likely conserved in mammals, further ONC analysis will inform our understanding of mammalian cancer etiology. Despite diverse genetic triggers, ONCs share many characteristics, including cell death, competition, and cooperation. The role of JNK in cell competition and its cooperation with Yki merits further study in both *Drosophila* and mammalian cancer models. The relationships between ONCs, Crb, p53, cellular senescence, and cell competition are exciting areas for future investigation. Notably, ONCs themselves do not directly contribute to cancer\'s effective population and hence do not undergo a Darwinian clonal selection. Instead, ONCs are created by the protective programs endowed with maintaining epithelial homeostasis: cell competition, cellular senescence, and apoptosis. We envision that ONCs contribute to non‐autonomous tumor initiation and progression through cooperation with adjacent premalignant tissue or through CSC induction or stimulation (Fig. [5](#cas12816-fig-0005){ref-type="fig"}). The basic genetic mechanisms uncovered in *Drosophila* ONCs likely underlie interclonal cooperation in heterogeneous mammalian cancers. Moreover, mammalian evidence suggests that ONCs fuel tumor recurrence following chemotherapy‐induced death or senescence. Therefore, cancer topography, the potential for ONC induction or subclone cooperation, must be carefully considered before individualized therapies become a reality.

Disclosure Statement {#cas12816-sec-0014}
====================

The authors have no conflict of interest.

The authors apologize for omitting relevant literature due to space constraints. The authors thank Shizue Ohsawa for providing unpublished data and the Igaki laboratory for helpful discussion during the manuscript\'s preparation. Research in T.I.\'s laboratory is supported by Grants‐in‐Aid for Scientific Research from the Japanese Ministry of Education, Science, Sports, Culture and Technology, Platform for Dynamic Approaches to Living System from the Japanese Ministry of Education, Science, Sports, Culture and Technology and the Japan Agency for Medical Research and Development, the Japan Society for the Promotion of Science, and PRESTO, Japan Science and Technology Agency.

[^1]: These authors contributed equally to this work.
